Another phase II study is also assessing the safety and efficacy of zanu with tafasitamab (a humanized monoclonal anti-CD19 antibody, recently approved by the FDA) in combination with lenalidomide for R/R diffuse large B-cell lymphoma (DLBCL) not eligible for stem cell transplantation (TaZa CLL Study; NCT05718869). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.